I seriously doubt it with the volume under 10K daily.
BTW Dancer Man, speaking of "puppet masters", you boys must have your marching orders with your uptick in bashing this week.
Nice to see that there was a 4% plus drop in shorts last report and to think, your little lackey was having a spasm over the prior report going up less than 1%.
"The short interest is up for the first time in quite a while. Not much, but the trend to cover has stopped."
I appreciate your inputs from a technical perspective and I'm not happy about the dilution either but what other choice do we have other than throw in the towel and let it go under? They need the funds to see this through and have no other means but to issue more shares.
One of my main concerns for the phase three is the unpredictability of the FDA. Even with excellent trial results, one never knows what excuse they may come up with to deny approval.
You have some very valid points and agree that in a sign of good faith, management should take a salary cut until profitable. I do disagree that another dilution will be in store prior to the phase three scleroderma being complete. Assuming phase three is completed in the 48 weeks as advertised, they presently have to my estimates around 24 plus mil in cash on hand plus or minus a mil. That's based upon the 9 mil reported from Q1, 16 and the 17 mil they just picked up from the offering. In addition, another 10 mil waiting from the warrants. Warrants can be held for 30 mths unless the stock holds over a certain value for 10 days so I realize the additional 10 may not be immediately available however, with that being said, at their present cash burn the 24 mil should carry them until phase three is complete and if phase three comes through as expected, that additional ten will be in the bank also because I think that even you would believe that the stock will definitely be above the required execution price for ten days at that point. Any additional financing from that point should be done with the company in a better position of strength. In addition, let us not forget the phase two OA coming in sometime later this year around the third or fourth quarter. Good results from that will surely spike the pps some. DOV has some pretty lofty numbers for his Excell projections and I can only hope that he is close to accurate with a slight profit for 2017 upon based I believe on company input. Granted, that is in disagreement with the annalist projections but a lot depends on the IDIS program and the revs it generates.
Your technical knowledge on the machine itself is better than mine and I'm basing my investment decisions for this primarily from info publish. My confusion with your post is why proclaim yourself being long when you appear to take a gleeful approach with bashers in anything negative about the company. If you are short, fine, so be it.
What's kind of interesting is that in spite of the recent drop, the warrant value is hanging in there around it's high. I would have thought that it would be down around 40 cents or lower with the recent pps drop.
From my understanding, they shelved the heart program for lack of funds and focused on the scleroderma which I'm sure they view as a more attainable potential for success and for revenue. I expect that if they get approval for scleroderma with rev and profits coming in, then they will gin up the heart program once again.
What I believe with small biotechs like this is that it is much like bucking city hall. You have big pharma involved with their money (and thus political clout) viewing any kind of break through technology as a threat to their turf.
We shall see, and if one of them hits, you'll be one of the first I let know as I am also sure that you and your buds will most gleefully let me know if and when they go BK.
In the meantime, perhaps you should make sure that you get your facts straight when trying to bash an innocent company into the ground instead of posting up a bunch of bogus smack.
I know Stem with what has been going on with this company that it is sometimes hard to take a wait and see approach but unfortunately, for those who are sticking with this company, we have no other choice.
I'm waiting to see if the good doctor Cugat will come out with a public announcement of his findings within a couple of months or so. It's his trial, his data and Cytori has no choice but to without a public announcement on something that they have had no control of.
Do you honestly believe that my entry and avg cost is anywhere near those lofty values?
If you do, then you are truly a "mental patient". 8)
"Adam F. is a genius, and he pays on time."
Did I mention anyone by name?
You're making counter productive statements my friend on being paid considering that your boss man contends that no basher here is being paid.
Patience, patience, patience
What I find rather amusing is your propensity to show up on MBs where a certain blogger is trashing a stock publicly.
BTW, how is that fake blogger ID working out for you or is that one of you buds?
Oh, so you have been bashing the stock from 2009? Care to share any other IDs that you have going back that far? I certainly don't recall biotech, mobil or any of the others you are running today going back to 2010.
"Cpt, were you the person who gave me a thumps-up rating on that post?"
I seriously doubt it because I can generally recognize when you are trying to be a smart aze.
Yahoo MO Summary page
Strike three General